News

Video

Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology

Author(s):

Caron Jacobson, MD,Miguel-Angel Perales, MD

Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.

Related Videos
Tracy George, MD
Elias Jabbour, MD
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Related Content
ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 12th 2024

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Smoldering Myeloma
December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Myelofibrosis | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 11th 2024

Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis

Polycythemia Vera | Image Credit: © ChaoticMind – stock.adobe.com
December 11th 2024

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET